Disease · MONDO_0003233
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| CX-8998 vs Placebo: deaths from any cause | 0 of 48 | 0 of 47 | 95 | NCT03101241 | Trial comparisons |
| CX-8998 vs Placebo: serious adverse events | 1 of 48 | 0 of 47 | 95 | NCT03101241 | Trial comparisons |
| Essential Tremor Treatment vs Parkinson Disease Tremor Treatment: deaths from any cause | 0 of 24 | 0 of 28 | 52 | NCT02427646 | Trial comparisons |
| Essential Tremor Treatment vs Parkinson Disease Tremor Treatment: serious adverse events | 0 of 24 | 0 of 28 | 52 | NCT02427646 | Trial comparisons |
| Pregabalin vs Placebo: serious adverse events | 0 of 20 | 0 of 18 | 38 | NCT00646451 | Trial comparisons |
| Octanoic Acid vs Placebo: deaths from any cause | 0 of 17 | 0 of 17 | 34 | NCT01864525 | Trial comparisons |
| Octanoic Acid vs Placebo: serious adverse events | 0 of 17 | 0 of 17 | 34 | NCT01864525 | Trial comparisons |
| IncobotulinumtoxinA 30 to 200 U vs Placebo: deaths from any cause | 0 of 19 | 0 of 11 | 30 | NCT02207946 | Trial comparisons |
| IncobotulinumtoxinA 30 to 200 U vs Placebo: serious adverse events | 0 of 19 | 2 of 11 | 30 | NCT02207946 | Trial comparisons |
| Flexors Alone vs Flexors Plus Extensors: deaths from any cause | 0 of 10 | 0 of 9 | 19 | NCT02909907 | Trial comparisons |
| Flexors Alone vs Flexors Plus Extensors: serious adverse events | 0 of 10 | 0 of 9 | 19 | NCT02909907 | Trial comparisons |
| CBD/THC vs Placebo: deaths from any cause | 0 of 7 | 0 of 7 | 14 | NCT03805750 | Trial comparisons |
| CBD/THC vs Placebo: serious adverse events | 0 of 7 | 0 of 7 | 14 | NCT03805750 | Trial comparisons |
| CBD/THC vs Placebo: Number of Participants With New Study-related Electrocardiogram (EKG) Abnormalities | 0 of 5 | 0 of 7 | 12 | NCT03805750 | Trial comparisons |
| CBD/THC vs Placebo: Number of Participants at Risk for Suicide Based on Columbia-Suicide Severity Rating Scale (C-SSRS) | 0 of 5 | 0 of 7 | 12 | NCT03805750 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003233/comparisons